Cover of the ebook

#Medsky🧪 #Drugsdiscovery
The significance of #mAbs in drug discovery and development - freeebook to download

7915828.fs1.hubspotusercontent-na1.net/hubfs/791582...

Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval The global research and pharmaceutical community rapidly mobilized to develop treatments for coronavirus disease 2019 (COVID-19). Existing treatments have been repurposed and new drugs have emerged. H...

Review of #COVID19 Therapeutics by Mechanism: From #DrugsDiscovery to Approval
💊 www.ncbi.nlm.nih.gov/pmc/articles...

#MedSky🧪#IDSky #Immunopharmacology #publichealth #Clinicalreview Summarize the major #Drugsdiscovery approaches, preclinical #antiviral evaluation models, representative virus-targeting , host-targeting therapeutic options

C-type lectin-like receptor 2: roles and drug target - Thrombosis Journal C-type lectin-like receptor-2 (CLEC-2) is a member of the C-type lectin superfamily of cell surface receptors. The first confirmed endogenous and exogenous ligands of CLEC-2 are podoplanin and rhodocy...

#Immunopharmacology #Drugsdiscovery Brief introduction of C-type lectin-like receptor 2: Roles & #drugsdevelopment that targeting #COVID19 , #Tumour , #DVT & the other diseases related #thrombosis thrombosisjournal.biomedcentral.com/articles/10....

E book

Contents

MedSky🧪 #Cancerresearch & #Drugsdiscovery .short summary of Breakthroughs in #Cancerresearch & recently #drugdiscovery ebook

7915828.fs1.hubspotusercontent-na1.net/hubfs/791582...

Clinical development of antivirals against SARS-CoV-2 and its variants The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although …

MedSky🧪 #IDSky #Drugsdiscovery #Drugsdevelopment #Immunopharmacology Summarize the latest advancements in the #clinicaldevelopment of #antivirals against infections by #SARSCoV2 and its variants.

www.sciencedirect.com/science/arti...

Medsky🧪#IDSky #Drugsdelivery #Drugsdiscovery @DDWJournal #NeuroCovid /#PostCovid19
#LongCovid sequelas that may now represent greater future challenges for healthcare systems & patient quality of life.

Path ways

MedSky🧪#Cancerbiology #Drugsdiscovery #Drugsdevelopment Understanding of targetable protein lipidation pathways in Cancer & mechanisms, dysregulation and emerging drug targets
www.nature.com/articles/s41...

The Next Generation of COVID-19 Vaccines May be Inhaled This Medical News story discusses experimental mucosal COVID-19 vaccines.

MedSky🧪IDSky #Drugsdiscovery #Drugsdevelopment Up the Nose and Down the Windpipe May Be the Path to New & Improved #COVID19Vaccines How these experimental #mucosalvaccines stack up against #mRNAvaccines and what’s in the pipeline ?

jamanetwork.com/journals/jam...

The life cycle of SARS-CoV-2 and targets for some antivirals. Entry-stage: SARS-CoV-2 particles use their Spike (S) protein to interact with receptor molecules (human ACE2) for viral entry. During the viral entry process, monoclonal antibodies can inhibit the interaction of S protein and ACE2 protein to inhibit viral entry, while TMPRSS-2 inhibitors and Cathepsin B/L inhibitors can inhibit proteolytic activation of spike protein to inhibit viral entry. Peptide inhibitors targeting HR1 (EK1 and HR2P) can inhibit 6-HB formation to block viral entry. Post-entry stage: Viral protein cleavage and RNA synthesis are important processes for the SARS-CoV-2 replication cycle. Mpro and PLpro are important proteases responsible for viral protein cleavage, and these processes can be halted by protease inhibitors, including, for example, nirmatrelvir (PF-07321332) and ensitrelvir. RdRp is important for viral RNA synthesis, and these processes can be stopped by RdRp inhibitors, such as remdesivir, VV

MedSky🧪IDSky #immunoSky #Drugsdevelopment #Drugsdiscovery Overview & Summaries of the clinical development of #antivirals targeting various factors to inhibit #SARSCoV2 infection, including both viral factors & host factors.